OTCMKTS:LTUS Lotus Pharmaceuticals (LTUS) Stock Price, News & Analysis $0.0040 0.00 (0.00%) As of 07/31/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Lotus Pharmaceuticals Stock (OTCMKTS:LTUS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lotus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0040▼$0.004050-Day Range N/A52-Week Range$0.0018▼$0.0098VolumeN/AAverage Volume8,594 shsMarket Capitalization$10.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lotus Pharmaceuticals, trading under the symbol LTUS on the OTC Market, is a Taiwan-based pharmaceutical company specializing in the research, development, manufacturing and marketing of prescription medications. The company’s core operations encompass both the production of a broad range of generic drugs and the advancement of novel compounds aimed at therapeutic areas such as oncology, central nervous system disorders, cardiovascular diseases and anti-infective treatments. Lotus Pharmaceuticals offers multiple dosage forms, including tablets, capsules, injectables and sterile preparations, to meet the needs of hospital and retail pharmacy channels. The company maintains an active internal R&D program, collaborating with external research organizations and academic institutions to move new molecular entities from preclinical stages into clinical trials while continuously expanding its generic portfolio. Headquartered in Tainan, Taiwan, Lotus Pharmaceuticals serves the domestic healthcare market and exports its products to key territories across Asia. By upholding international quality standards and pursuing strategic partnerships, the company aims to strengthen its geographic reach and enhance its pipeline of innovative and cost-effective therapeutic solutions.AI Generated. May Contain Errors. Read More Receive LTUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lotus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LTUS Stock News HeadlinesLotus Pharmaceuticals Inc (LTUS)July 1, 2026 | nasdaq.comLotus Pharmaceuticals Inc.March 31, 2026 | barrons.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.August 2 at 1:00 AM | Porter & Company (Ad)Boryung Acquires Taxotere Global Business to Expand into 19 CountriesOctober 29, 2025 | msn.comAvalo Therapeutics completes enrollment in Phase 2 LOTUS trialOctober 29, 2025 | msn.comAlvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics PlatformSeptember 23, 2025 | finance.yahoo.comAcadia Pharmaceuticals publishes interim LOTUS study data in journalSeptember 12, 2025 | msn.comReal World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental ...September 12, 2025 | finance.yahoo.comSee More Headlines LTUS Stock Analysis - Frequently Asked Questions How have LTUS shares performed this year? Lotus Pharmaceuticals' stock was trading at $0.0030 at the beginning of the year. Since then, LTUS stock has increased by 31.7% and is now trading at $0.0040. How do I buy shares of Lotus Pharmaceuticals? Shares of LTUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lotus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lotus Pharmaceuticals investors own include Vodafone Group (VOD), TILT (TLLTF), NextEra Energy (NEE), Energy Transfer (ET) and Ameriwest Lithium (AWLID). Company Calendar Today8/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:LTUS CIKN/A Webwww.lotuspharma.com Phone(941) 267-9684Fax86-10-6389-9867Employees230Year Founded1966Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares2,644,520,000Free FloatN/AMarket Cap$10.45 million OptionableNot Optionable Beta-1.61 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:LTUS) was last updated on 8/2/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA New Gold Era Is Coming - Here's How to Help Protect Your Retirement NowWashington insiders are quietly talking about a coordinated move to revalue gold—and with the national debt ap...Preserve Gold | SponsoredAI is not overTesla and Alphabet just tumbled, and many investors concluded AI is over. It isn't - the easy AI trade may be....The Oxford Club | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredThe dollar just brokeBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lotus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lotus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LTUS Stock Alerts